Log in

Start Your Membership Now

October 7, 2010 Researchers with the McMaster University Evidence Based Practice Center released a draft report that found that adding an atypical antipsychotic medication was found to be an effective second step for persons first treated for depression with an SSRI, but who failed to respond. Higher response and remission rates after the addition of an atypical antipsychotic, compared to adding a placebo, were supported by moderate grade evidence. Switching to another antidepressant was supported by low-grade evidence, as was combining cognitive behavioral therapy with an antidepressant. Comments on the report will be accepted through November 3, 2010. Download . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | October 7, 2010

Comparative Effectiveness of Treatment for Depression after Unsatisfactory Response to SSRIs when used as First-line Therapy

October 7, 2010 Researchers with the McMaster University Evidence Based Practice Center released a draft report that found that adding an atypical antipsychotic medication was found to be an effective second step for persons first treated for depression with an SSRI, but who failed to respond. Higher response and remission rates after the addition of an atypical antipsychotic, compared to adding a placebo, were supported by moderate grade evidence. Switching to another antidepressant was supported by low-grade evidence, as was combining cognitive behavioral therapy with an antidepressant. Comments on the report will be accepted through November 3, 2010. Download . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.